The Shuman Law Firm Investigates BioMimetic Therapeutics, Inc.

BOULDER, Colo.--(BUSINESS WIRE)--The Shuman Law Firm today announced that it is investigating potential claims against certain officers and directors of BioMimetic Therapeutics, Inc. (“BioMimetic” or the “Company”) (NASDAQ: BMTI). BioMimetic is a biotechnology company specializing in the development and commercialization of products to promote the healing of musculoskeletal injuries and diseases.

The Shuman Law Firm’s investigation focuses on allegations raised in a class action lawsuit filed in the U.S. District Court for the Middle District of Tennessee on behalf of purchasers of BioMimetic common stock between October 14, 2009 and May 11, 2011.

The lawsuit alleges that BioMimetic and certain of its officers and/or directors misrepresented and/or failed to disclose: (a) material facts about the Company's business, operations, management and future business prospects; (b) material facts about the safety and efficacy of the Company’s lead product—Augment® Bone Graft (“Augment”)—and its prospects for FDA approval; and (c) possible inadequacies of Augment's clinical trial, including that BioMimetic deviated from the protocol agreement with the FDA; the sample size of the trial was too small to provide verifiable results; and the results of the clinical trial were not statistically significant.

If you currently own shares of Biomimetic common stock and are interested in discussing your rights as a shareholder, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll free at (866) 974-8626 or email Mr. Shuman at kip@shumanlafirm.com or email Mr. Glenn at rusty@shumanlawfirm.com.

The Shuman Law Firm represents investors throughout the nation, concentrating its practice in securities class actions and shareholder derivative actions.